A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Relapsing-remitting multiple sclerosis (RR-MS) is a chronic autoimmune disease affecting the central nervous system.
• Interferon-beta (IFNbeta) is a common treatment for RR-MS, with various formulations and administration schedules available.
• Optimizing IFNbeta treatment efficacy requires understanding the impact of different administration types, doses, and frequencies.

Purpose of the Study:

• To compare the clinical efficacy of two different interferon-beta formulations in patients with RR-MS.
• To determine if the dose and frequency of interferon-beta administration influence treatment outcomes in RR-MS.
• To evaluate the impact of different interferon-beta treatments on relapse rates, time to relapse, and disease progression.

Main Methods:

• A multicenter, controlled, open-label, randomized head-to-head study comparing subcutaneous IFNbeta-1a (22 mcg weekly) with IFNbeta-1b (250 mcg every other day) for 24 months.
• Inclusion criteria: definite MS, at least two relapses in 2 years, age 18-55, EDSS score ≤5.5.
• A non-randomized group received IFNbeta-1b (250 mcg every other day). Primary endpoints: annualized relapse rate, time to first relapse, neutralizing antibody formation. Secondary endpoint: time to sustained progression.

Main Results:

• Annualized relapse rates were similar between randomized groups (IFNbeta-1a: 0.70; IFNbeta-1b: 0.71).
• Time to first relapse and time to sustained progression were comparable in the randomized arms.
• In the non-randomized IFNbeta-1b group, the annualized relapse rate was not significantly different, but the time to progression was shorter.

Conclusions:

• The study found no significant clinical superiority of 250 mcg of interferon-beta-1b administered every other day compared to 22 mcg of interferon-beta-1a administered weekly for RR-MS.
• Treatment efficacy in RR-MS may be influenced by factors beyond type, dose, and frequency, warranting further investigation.
• Both evaluated interferon-beta treatments demonstrated comparable outcomes in managing relapsing-remitting multiple sclerosis in this cohort.